Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Income towards Parent Company (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Income towards Parent Company for 3 consecutive years, with -$20.8 million as the latest value for Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 29.09% year-over-year to -$20.8 million; the TTM value through Dec 2025 reached -$83.9 million, down 35.39%, while the annual FY2025 figure was -$83.9 million, 28.27% down from the prior year.
  • Income towards Parent Company hit -$20.8 million in Q4 2025 for Artiva Biotherapeutics, up from -$21.5 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $13.3 million in Q4 2023 and bottomed at -$21.5 million in Q3 2025.
  • Average Income towards Parent Company over 3 years is -$12.1 million, with a median of -$16.1 million recorded in 2024.
  • Year-over-year, Income towards Parent Company crashed 246.84% in 2024 and then decreased 29.09% in 2025.
  • Artiva Biotherapeutics' Income towards Parent Company stood at $13.3 million in 2023, then crashed by 221.42% to -$16.1 million in 2024, then decreased by 29.09% to -$20.8 million in 2025.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at -$20.8 million, -$21.5 million, and -$21.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.